Results 61 to 70 of about 1,203 (200)
Advances in the Treatment of Invasive Fungal Disease [PDF]
, 2023 With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases (IFDs) are a major medical burden and source of global morbidity and mortality.
An, Zhiqiang +2 more
core +1 more source
Hope on the horizon: Novel fungal treatments in development [PDF]
, 2020 The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies including toxicity, interactions, restricted routes of administration, and drug resistance.
Coler-Reilly, Ariella +3 more
core +1 more source
Rezafungin—mechanisms of action, susceptibility and resistance: Similarities and differences with the other echinocandins [PDF]
, 2020 Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. It is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by
Garcia, Guillermo Manuel
core +1 more source
Emerging and Future Strategies in the Management of Recalcitrant Candida auris [PDF]
, 2022 Candida auris is an emerging, multi drug resistant fungal pathogen that has caused infectious outbreaks in over 45 countries since its first isolation over a decade ago, leading to in-hospital crude mortality rates as high as 72%.
Bandara, Nihal, Samaranayake, Lakshman
core +3 more sources
Fungal Cell Wall: Emerging Antifungals and Drug Resistance
Frontiers in Microbiology, 2019 The cell wall is an essential component in fungal homeostasis. The lack of a covering wall in human cells makes this component an attractive target for antifungal development. The host environment and antifungal stress can lead to cell wall modifications
Soraia L. Lima +2 more
doaj +1 more source
Therapeutic tools for oral candidiasis : current and new antifungal drugs [PDF]
, 2019 Candidiasis is one of the most common opportunistic oral infections that presents different acute and chronic clinical presentations with diverse diagnostic and therapeutic approaches.
Eraso Barrio, Elena +6 more
core +1 more source
Journal of Fungi, 2022 Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj +1 more source
In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations [PDF]
Antimicrobial Agents and Chemotherapy, 2019 Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins.
Natalie S. Nunnally +4 more
openalex +3 more sources
Candida auris: a quick review on identification, current treatments, and challenges [PDF]
, 2021 Candida auris is a novel and major fungal pathogen that has triggered several outbreaks in the last decade. The few drugs available to treat fungal diseases, the fact that this yeast has a high rate of multidrug resistance and the occurrence of ...
Brás, Susana Maria Pereira +4 more
core +1 more source